PROVIROMICS
DEAD

Serial Number

97237382

Owner

Retroviral Therapeutics LLC

Attorney

Thomas E. Kenney

Filing Date

Jan 25, 2022

Add to watchlist:

No watchlists yet
View on USPTO

PROVIROMICS Trademark

Serial Number: 97237382

PROVIROMICS is a trademark filed by Retroviral Therapeutics LLC on January 25, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Retroviral Therapeutics LLC (5 trademarks)

12 Smith Hill Road
Lincoln, MA 01773

Entity Type: 16

Trademark Details

Filing Date

January 25, 2022

Registration Date

Not Registered

Published for Opposition

January 24, 2023

Goods & Services

Vaccines; Biological preparations for the treatment of diseases, disorders and illnesses, namely, cancer, osteoporosis, kidney diseases, liver diseases, viral infections, infectious diseases, and retroviruses; Medical preparations for the treatment of diseases, disorders and illnesses, namely, infectious diseases, cancer, osteporosis, kidney diseases, liver diseases, viral infections, and for use in oncology and retroviruses; Pharmaceutical preparations for the treatment of diseases, disorders and illnesses, namely, cancer, osteoporosis, kidney diseases, liver diseases, viral infections, infectious diseases, and retroviruses; Therapeutic pharmaceuticals for the treatment of diseases, disorders and illnesses, namely, cancer, osteoporosis, kidney diseases, liver diseases, viral infections, infectious diseases, and retroviruses; Therapeutic vaccines

Scientific and technological services, namely, testing in the field of viruses used for clinical and treatment purposes in the nature of virus testing for medical diagnostic or treatment purposes

Bacteriological research and analysis; Bacteriological research and testing; Consulting services for others in the field of design, planning, and implementation project management of scientific research and clinical trials involving viruses used for clinical and treatment purposes; Consulting services in the fields of biotechnology, pharmaceutical research and development, and pharmacogenetics; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific and technological services, namely, design, engineering, research, development and testing in the field of immunopharmaceuticals and vaccines involving viruses used for clinical and treatment purposes

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 28, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 28, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 21, 2024 EXRA
SOU EXTENSION 2 GRANTED
Mar 20, 2024 EX2G
SOU EXTENSION 2 FILED
Mar 20, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 20, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 21, 2023 EXRA
SOU EXTENSION 1 GRANTED
Sep 19, 2023 EX1G
SOU EXTENSION 1 FILED
Sep 19, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 19, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 21, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 24, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jan 24, 2023 PUBO
ASSIGNED TO EXAMINER
Jan 20, 2023 DOCK
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 4, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 16, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 16, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 16, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 16, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 16, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 14, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 14, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 14, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 14, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jun 14, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jun 14, 2022 CNRT
ASSIGNED TO EXAMINER
May 24, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 31, 2022 NWOS
NEW APPLICATION ENTERED
Jan 28, 2022 NWAP